Immediate Treatment vs Colposcopic Follow-up for Biopsy-Proven CIN 1


This study looks at immediate treatment of a cervix with CIN 1 versus regular six-month follow-up with colposcopy and treatment if CIN 1 progresses.

Full Title of Study: “Randomized Trial of Immediate Treatment vs. Colposcopic Follow-up for Biopsy-Proven CIN 1″

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: September 2007

Detailed Description

In women who present with biopsy-proven CIN 1, to compare the management approach of regular colposcopic follow-up and only treating progressive disease using the LEEP, with an approach of immediate treatment using LEEP. The primary outcome is progression to more advanced disease (i.e., CIN 2, CIN 3 or cancer).


  • Procedure: loop electrosurgical excision procedure (LEEP)
    • 1. loop electrosurgical excision procedure

Arms, Groups and Cohorts

  • Experimental: 1
    • Immediate Treatment – LEEP – Loop electrosurgical excision procedure
  • No Intervention: 2
    • Colposcopic Follow-up

Clinical Trial Outcome Measures

Primary Measures

  • progression to more advanced disease
    • Time Frame: 18 months

Secondary Measures

  • persistent CIN 1 after 18 months
    • Time Frame: 18 months
  • bleeding.
    • Time Frame: 18 months
  • predict disease persistence or progression
    • Time Frame: 18 months

Participating in This Clinical Trial

Inclusion Criteria

  • Eligible patients will:
  • have documented CIN 1 by histologic assessment as the highest grade lesion present,
  • have the lesion confined to the cervix and completely visualized,
  • be 16 years or older.

Exclusion Criteria

  • any one of the following will be an excluding characteristic:
  • index Pap smear showing CIN 2, CIN 3 or cancer;
  • index Pap smear shows atypical glandular cells of unknown significance, glandular dysplasia, or malignancy requiring immediate investigation;
  • patients with previously identified CIN 1 by biopsy who are already in a colposcopic surveillance program;
  • unsatisfactory colposcopic exam defined as inability to see the extent of the lesion in the endocervical canal or absence of a lesion on the ectocervix but endocervical curettage shows CIN 1;
  • pregnancy;
  • prior therapy for dysplasia including medical (5FU), surgical (Laser, LEEP) or cryotherapy;
  • prior gynecologic cancer;
  • prior pelvic radiation therapy;
  • inability to attend outpatient follow-up visits because of geographic inaccessibility;
  • other malignancies except non-melanoma skin cancer;
  • immunosuppression due to diseases such as AIDS, organ transplantation, or on immunosuppressive medications such as prednisone, imuran or chemotherapy for diseases like systemic lupus;
  • cognitively impaired or otherwise unable to obtain written informed consent;
  • extension of the CIN 1 lesion to vagina or a separate vaginal lesion showing dysplasia;
  • colposcopically visible condyloma outside of the transformation zone;
  • known allergy to local analgesics;
  • clinically evident vaginitis must be treated and resolved prior to entry on the trial;
  • inability to read and respond in English/French;
  • failure to provide informed consent.

Gender Eligibility: Female

Minimum Age: 16 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Ontario Clinical Oncology Group (OCOG)
  • Collaborator
    • Canadian Institutes of Health Research (CIHR)
  • Provider of Information About this Clinical Study
    • Dr. Mark Levine, Ontario Clinical Oncology Group
  • Overall Official(s)
    • Laurie Elit, MD, Study Chair, Juravinski Cancer Centre
    • Mark Levine, MD, Principal Investigator, Ontario Clinical Oncology Group (OCOG)
    • Jim Julian, MMath, Principal Investigator, McMaster University, Dept of Clinical Epidemiology & Biostatistics

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.